Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma (1999)

Peer-Reviewed Study · Jan C. Buckner, Mark G. Malkin, Elizabeth Reed, Teresa L. Cascino, et al. (Mayo Clinic) · February 1999

Jan C. Buckner et al., 1999-02: Independent Mayo Clinic phase II trial of antineoplastons A10 and AS2-1 in recurrent anaplastic astrocytoma or glioblastoma: nine patients treated, six assessable, no tumour regression, with grade 2-3 neurocortical toxicity in five.

Nine patients were treated, in six of whom the treatment response was assessable in accordance with protocol stipulations. No patient demonstrated tumor regression.

Abstract, unpaginated web record

Jan C. Buckner et al., 1999-02: Independent Mayo Clinic phase II trial of antineoplastons A10 and AS2-1 in recurrent anaplastic astrocytoma or glioblastoma: nine patients treated, six assessable, no tumour regression, with grade 2-3 neurocortical toxicity in five. Funder: not stated in the abstract; conducted at Mayo, using NCI NSC numbers for the agents (NSC 648539, NSC 620261), which indicates NCI drug-development registration. Maker: Burzynski Research Institute supplied the antineoplastons. Comparator: none – single-arm phase II; the authors state the small sample 'precludes definitive conclusions about treatment efficacy'. Conflicts: none declared. This is the outside replication Burzynski's own papers never received. Study type: uncontrolled series.